Lisheng Chen1,2, Ruilin Wang3, Honghong Liu4, Shizhang Wei1, Manyi Jing1, Min Wang1, Yanling Zhao1. 1. Department of Pharmacy, Fifth Medical Center, General Hospital of Chinese PLA, Beijing, China. 2. Department of Pharmacy, Hebei North University, Zhangjiakou, China. 3. Department of Traditional Chinese Medicine, Fifth Medical Center, General Hospital of Chinese PLA, Beijing, China. 4. Integrative Medical Center, Fifth Medical Center, General Hospital of Chinese PLA, Beijing, China.
Abstract
OBJECTIVE: The systematic review was designed to evaluate the safety and efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in the treatment of chronic heart failure (CHF). METHODS: Relevant randomized controlled trials (RCTs) investigating the clinical efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in treating CHF were widely searched in electronic databases, including PubMed, Cochrane Library, EMBASE, CBM, CNKI, Read-show database, VIP database, and WanFang up to December 26, 2020. The methodological quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0. Meta-analysis was performed by using Review Manager 5.3. RESULTS: Twenty-one RCTs (N = 2162) that met the criteria were included in the review for the assessment of methodological quality. Meta-analysis showed that compared with the conventional Western medicine (control group), Qishen Yiqi dropping pill combined with conventional Western medicine (experience group) significantly improved clinical efficiency, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), brain natriuretic peptide level (BNP), 6 min-walk distance (6-MWD), and adverse reactions. CONCLUSION: Qishen Yiqi dropping pill combined with conventional Western medicine are better than conventional Western medicine alone to improve the indicators of patients with CHF, which provides a certain basis for the treatment of CHF.
OBJECTIVE: The systematic review was designed to evaluate the safety and efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in the treatment of chronic heart failure (CHF). METHODS: Relevant randomized controlled trials (RCTs) investigating the clinical efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in treating CHF were widely searched in electronic databases, including PubMed, Cochrane Library, EMBASE, CBM, CNKI, Read-show database, VIP database, and WanFang up to December 26, 2020. The methodological quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0. Meta-analysis was performed by using Review Manager 5.3. RESULTS: Twenty-one RCTs (N = 2162) that met the criteria were included in the review for the assessment of methodological quality. Meta-analysis showed that compared with the conventional Western medicine (control group), Qishen Yiqi dropping pill combined with conventional Western medicine (experience group) significantly improved clinical efficiency, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), brain natriuretic peptide level (BNP), 6 min-walk distance (6-MWD), and adverse reactions. CONCLUSION: Qishen Yiqi dropping pill combined with conventional Western medicine are better than conventional Western medicine alone to improve the indicators of patients with CHF, which provides a certain basis for the treatment of CHF.
Authors: Amy K Saenger; Olaia Rodriguez-Fraga; Ranka Ler; Jordi Ordonez-Llanos; Allan S Jaffe; Jens Peter Goetze; Fred S Apple Journal: Clin Chem Date: 2016-11-15 Impact factor: 8.327
Authors: Stephan Gielen; Marcus Sandri; Irina Kozarez; Jürgen Kratzsch; Daniel Teupser; Joachim Thiery; Sandra Erbs; Norman Mangner; Karsten Lenk; Rainer Hambrecht; Gerhard Schuler; Volker Adams Journal: Circulation Date: 2012-05-07 Impact factor: 29.690
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18